Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
| 34.73 | |
| 35.41 | |
| - | |
| 35.7664 | |
| 34.705 | |
| 6.4-47.45 | |
| 3 487 M | |
| 100 M | |
| 0 | |
| -0.7 | |
| 1.054 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Dyne Therapeutics, Inc. - Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWS...
We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now.In this article, we are going to take a look at where Dyne Therapeutics, Inc. (NASDAQ:DYN) stands against the other hot stocks. ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
